Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Proline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 7/20 | 0.34 |
| ▸ | NPY1R | P25929 | 5/20 | 0.34 |
| ▸ | PRCP | P42785 | 2/20 | 0.33 |
| ▸ | NPY2R | P49146 | 4/20 | 0.32 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Leucine SCHEMBL5702941 | 0.90 | MAPK8 (0.30) | — | |
| Arginine SCHEMBL1697257 | 0.88 | PRCP (0.38) | NPY4RNPY1RPRCPNPY2RNPY5R | |
| Arginine SCHEMBL28419523 | 0.88 | PRCP (0.38) | NPY4RNPY1RPRCPNPY2RNPY5R | |
| Glutamine SCHEMBL5702907 | 0.86 | KDM1A (0.31) | — | |
| Arginine SCHEMBL2459501 | 0.86 | PRCP (0.37) | NPY4RNPY1RPRCPNPY2RNPY5R | |
| Arginine SCHEMBL29141605 | 0.85 | KDM1A (0.34) | NPY4RNPY1RPRCPNPY2RNPY5R | |
| Leucine SCHEMBL7037614 | 0.85 | PRCP (0.31) | NPY4RNPY1RPRCP | |
| Arginine SCHEMBL28736891 | 0.85 | KDM1A (0.32) | NPY4RNPY1RPRCPNPY2RNPY5R | |
| Arginine SCHEMBL8628358 | 0.84 | PRCP (0.35) | NPY4RNPY1RPRCPNPY2RNPY5R | |
| Arginine SCHEMBL28552748 | 0.84 | PRCP (0.35) | NPY4RNPY1RPRCPNPY2RNPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2000029009-A9 | PEPTIDES HAVING ANTI-CANCER AND ANTI-INFLAMMATORY ACTIVITY | COASTSIDE BIO RESOURCES (US) | 2001-12-13 | — | — | WO | claimed |
| WO-2000029009-A1 | PEPTIDES HAVING ANTI-CANCER AND ANTI-INFLAMMATORY ACTIVITY | COASTSIDE BIO RESOURCES (US) | 2000-05-25 | — | — | WO | claimed |
| US-20060193847-A1 | Peptides for inhibiting retroviruses | HOWARD MARK E | 2006-08-31 | — | — | US | disclosed |
| US-6767890-B1 | ADMINISTERING LEU-PRO-PRO-SER-ARG PENTAPEPTIDE | COASTSIDE BIO RESOURCES | 2004-07-27 | — | — | US | disclosed |
| US-6767890-B1 | ADMINISTERING LEU-PRO-PRO-SER-ARG PENTAPEPTIDE | COASTSIDE BIO RESOURCES | 2004-07-27 | — | — | US | disclosed |
| US-20030091586-A1 | Peptides for inhibiting retroviruses | HOWARD MARK E (US) | 2003-05-15 | — | — | US | disclosed |
| EP-0971726-A4 | PEPTIDES FOR INHIBITING RETROVIRUSES | HOWARD MARK E (US) | 2002-07-24 | — | — | EP | disclosed |
| US-20020037326-A1 | Useful for inhibiting diseases associated with retroviral infection, such as acquired immunodeficiency syndrome, also inhibit growth of tumor cells, especially sarcomas and leukemias | ZORION CORP. | 2002-03-28 | — | — | US | disclosed |
| WO-2000029009-A9 | PEPTIDES HAVING ANTI-CANCER AND ANTI-INFLAMMATORY ACTIVITY | COASTSIDE BIO RESOURCES (US) | 2001-12-13 | — | — | WO | disclosed |
| WO-2000029009-A9 | PEPTIDES HAVING ANTI-CANCER AND ANTI-INFLAMMATORY ACTIVITY | COASTSIDE BIO RESOURCES (US) | 2001-12-13 | — | — | WO | disclosed |
| WO-2000029009-A1 | PEPTIDES HAVING ANTI-CANCER AND ANTI-INFLAMMATORY ACTIVITY | COASTSIDE BIO RESOURCES (US) | 2000-05-25 | — | — | WO | disclosed |
| WO-2000029009-A1 | PEPTIDES HAVING ANTI-CANCER AND ANTI-INFLAMMATORY ACTIVITY | COASTSIDE BIO RESOURCES (US) | 2000-05-25 | — | — | WO | disclosed |
| EP-0971726-A1 | PEPTIDES FOR INHIBITING RETROVIRUSES | Howard, Mark E. (US) | 2000-01-19 | — | — | EP | disclosed |
| WO-1998017301-A1 | PEPTIDES FOR INHIBITING RETROVIRUSES | HOWARD MARK E (US) | 1998-04-30 | — | — | WO | disclosed |